Blenrep is a cancer medicine used to treat multiple myeloma (a cancer of the bone marrow). It is given to adults who have received at least four previous treatments and whose disease does not respond to treatment with at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody (types of cancer medicines), and whose cancer has worsened since receiving the last treatment.<\/p>\n
Multiple myeloma is rare, and Blenrep was designated an \u2018orphan medicine<\/a>\u2019 (a medicine used in rare diseases) on 16 October 2017.\u00a0Blenrep contains the\u00a0active substance<\/a>\u00a0belantamab mafodotin.<\/p>\n To access belantamab mafodotin-blmf for injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n Blenrep (belantamab mafodotin-blmf) is a medication used for the treatment of adult patients with relapsed or refractory multiple myeloma whose disease has progressed despite prior treatment with an immunomodulatory agent, proteasome inhibitor and anti-CD38 antibody.<\/p>\n Facts about belantamab mafodotin-blmf for injection<\/strong><\/p>\n Disease Indications-Multiple Myeloma If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import “belantamab mafodotin-blmf for injection\u201d based on the information you provide.<\/strong><\/p>\nHow can 1 go about obtaining belantamab mafodotin-blmf for injection?<\/h3>\n
BLENREP (belantamab mafodotin-blmf) for injection, for intravenous use Initial U.S. Approval: 2020<\/h5>\n","protected":false},"excerpt":{"rendered":"
belantamab mafodotin-blmf
\nfor injection, for intravenous use Initial U.S. Approval: 2020<\/h2>\n
\nManufacturer-GlaxoSmithKline
\nUsage-Intravenous
\nMedicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n